Dual inhibition: A novel promising pharmacological approach for different disease conditions

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 4, 2011, Pages 459-471

  Patyar, Sazal ^a   Prakash, Ajay ^a   Medhi, Bikash ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

10 METHYLACRIDINIUM IODIDE; 2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; 3 [4 [(BENZYL(METHYL)AMINO)METHYL]PHENYL] 6,7 DIMETHOXY 2H 2 CHROMENONE; AMISULPRIDE; AMLODIPINE; AP 2238; BOSENTAN; BUCINDOLOL; CARVEDILOL; CILNIDIPINE; DRONABINOL; EFONIDIPINE; FASIDOTRIL; FUMARIC ACID; ISAINDIGOTONE DERIVATIVE; LABETALOL; LADOSTIGIL; LCZ 696; MONOAMINE OXIDASE INHIBITOR; N [1 BENZYL 2 HYDROXY 3 [2 (1 BENZYLPIPERIDIN 4 YL)ETHYLAMINO]PROPYL] 5 [METHYL(METHYLSULFONYL)AMINO] N' [1 PHENYLETHYL]ISOPHTHALAMIDE; NICOTINIC ACID; NIFEDIPINE; PALIPERIDONE; PAPAVERINE; PMS 777; PROTEIN INHIBITOR; RIVASTIGMINE; RS 1259; SEROTONIN UPTAKE INHIBITOR; TACRINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALZHEIMER DISEASE; ANGINA PECTORIS; BLOOD CLOT LYSIS; CARDIOVASCULAR EFFECT; CONGESTIVE HEART FAILURE; DEPRESSION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ESSENTIAL HYPERTENSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATORY DISEASE; LOW DRUG DOSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POLYPHARMACY; PROCESS DEVELOPMENT; PROTEIN LOCALIZATION; PSYCHOSIS; PULMONARY HYPERTENSION; REVIEW; SCHIZOPHRENIA; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY; DRUGS, INVESTIGATIONAL; HUMANS; MOLECULAR STRUCTURE; PRESCRIPTION DRUGS;

EID: 79952722267     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01236.x     Document Type: Review

References (95)

1. Haider SI et al. The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600 000 older people. J Am Geriatr Soc 2009; 57: 62-69.
2. Cooney D, Pascuzzi K. Polypharmacy in the elderly: focus on drug interactions and adherence in hypertension. Clin Geriatr Med 2009; 25: 221-233.
3. Kamal MA et al. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis 2006; 10: 43-51. (Pubitemid 44401365)
4. Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract 2002; 56: 206-214. (Pubitemid 34477205)
5. Venneri A et al. Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport 2005; 16: 107-110. (Pubitemid 40250379)
6. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47: 64-70.
7. Bartorelli L et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 2005; 21: 1809-1818.
8. Camps P et al. Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J Med Chem 2005; 48: 1701-1704. (Pubitemid 40396300)
9. Soukup O et al. Methylacridinium and its cholinergic properties. Neurotox Res 2009; 16: 372-377.
10. Pan L et al. Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett 2008; 18: 3790-3793. (Pubitemid 351794508)
11. Jinghui L et al. Effects of metabolites of mangrove fungus Xylaria sp. from South China Sea Coast on the activity of acetylcholinesterase in vitro. Zhong Yao Cai 2004; 27: 261-264.
12. Brühlmann C et al. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J Med Chem 2001; 44: 3195-3198. (Pubitemid 32862350)
13. Ucar G et al. 1-N-Substituted thiocarbamoyl-3-phenyl-5- thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci Lett 2005; 382: 327-331. (Pubitemid 40733646)
14. Brühlmann C et al. Screening of non-alkaloidal natural compounds as acetylcholinesterase inhibitors. Chem Biodivers 2004; 1: 819-829.
15. Toda N et al. Dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimer's disease. In: Chan AP, ed. Alzheimer's Disease Research Trends. New York: Nova Sci publishers, 2008: 57-89.
16. Piazzi L et al. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)- 6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J Med Chem 2003; 46: 2279-2282. (Pubitemid 36637912)
17. Dorronsoro I et al. Synthesis and biological evaluation of tacrine-thiadiazolidinone hybrids as dual acetylcholinesterase inhibitors. Arch Pharm (Weinheim) 2005; 338: 18-23. (Pubitemid 40364647)
18. Bolognesi ML et al. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation. J Med Chem 2005; 48: 24-27. (Pubitemid 40105245)
19. Marco-Contelles J et al. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. J Med Chem 2009; 52: 2724-2732.
20. Inestrosa NC et al. Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo red and the role of the Wnt pathway. Curr Alzheimer Res 2005; 2: 301-306. (Pubitemid 40980188)
21. Haviv H et al. Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors. Curr Top Med Chem 2007; 7: 375-387. (Pubitemid 46358650)
22. Li W et al. Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors. J Biol Chem 2005; 280: 18179-18188. (Pubitemid 41389063)
23. Zhu Y et al. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta -secretase. Bioorg Med Chem 2009; 17: 1600-1613.
24. Ezoulin MJ et al. Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells. Neurosci Lett 2005; 389: 61-65. (Pubitemid 41242886)
25. Grauer SM et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 2009; 331: 574-590.
26. Petzer JP et al. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics 2009; 6: 141-151.
27. Pretorius J et al. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4- phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem 2008; 16: 8676-8684.
28. Altavilla D et al. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages. Br J Pharmacol 2009; 157: 1410-1418.
29. Gay RE et al. Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. J Rheumatol 2001; 28: 2060-2065. (Pubitemid 32803785)
30. Trippodo NC et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995; 275: 745-752. (Pubitemid 26027044)
31. French JF et al. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther 1994; 268: 180-186. (Pubitemid 24039086)
32. Gonzalez W et al. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. J Pharmacol Exp Ther 1996; 278: 573-581. (Pubitemid 27167021)
33. Kai T, Kuzumoto Y. Effects of a dual L/N-type calcium channel blocker cilnidipine on blood pressure, pulse rate, and autonomic functions in patients with mild to moderate hypertension. Clin Exp Hypertens 2009; 31: 595-604.
34. Emoto N et al. Dual ECE/NEP inhibition on cardiac and neuro-humoral function during the transition from hypertrophy to heart failure in rats. Hypertension 2005; 45: 1145-1152. (Pubitemid 40770319)
35. Tabrizchi R. SLV-306. Solvay. Curr Opin Investig Drugs 2003; 4: 329-332.
36. Perico N et al. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int 2009; 76: 960-967.
37. Rehman A. A unique dual acting inhibitor for thrombosis: combining anticoagulant & antiplatelet effects into a single molecule. In: Non-Confidential Dossier. Medicure Inc, 2008.
38. Ray S et al. Dual inhibition of DNA topoisomerases of Leishmania donovani by novel indolyl quinolines. Biochem Biophys Res Commun 1997; 230: 171-175. (Pubitemid 27210266)
39. Wang J et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci USA 2007; 104: 7612-7616. (Pubitemid 47185954)
40. Marchand C et al. Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H. Antimicrob Agents Chemother 2008; 52: 361-364.
41. Wang QM et al. Dual inhibition of human rhinovirus 2A and 3C proteases by homophthalimides. Antimicrob Agents Chemother 1998; 42: 916-920. (Pubitemid 28216379)
42. Park S et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 2008; 22: 1698-1706.
43. Maira SM et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-1863.
44. Li T et al. WJD008, a Dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J Pharmacol Exp Ther 2010; 334: 830-838.
45. Weisberg E et al. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 2008; 111: 3723-3734.
46. Denny WA. Dual topoisomerase I/II poisons as anticancer drugs. Expert Opin Investig Drugs 1997; 6: 1845-1851. (Pubitemid 27517588)
47. Fujimoto S. Promising antitumor activity of a novel quinoline derivative, TAS-103, against fresh clinical specimens of eight types of tumors measured by flow cytometric DNA analysis. Biol Pharm Bull 2007; 30: 1923-1929. (Pubitemid 47607787)
48. Yanagihara M et al. Leptosins isolated from marine fungus Leptoshaeria species inhibit DNA topoisomerases I and/or II and induce apoptosis by inactivation of Akt/protein kinase B. Cancer Sci 2005; 96: 816-824. (Pubitemid 43019833)
49. Sargent JM et al. Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs 2003; 14: 467-473. (Pubitemid 36951799)
50. Mistry P et al. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs 2002; 13: 15-28. (Pubitemid 34169523)
51. Wiedmann M et al. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 2006; 17: 783-795. (Pubitemid 44310175)
52. Griessinger E et al. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells. Leukemia 2007; 21: 877-885. (Pubitemid 46672062)
53. Carreiras MC, Marco JL. Recent approaches to novel anti-Alzheimer therapy. Curr Pharm Des 2004; 10: 3167-3175. (Pubitemid 39242911)
54. Yogev-Falach M et al. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 2006; 20: 2177-2179.
55. Youdim MB et al. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 2005; 126: 317-326. (Pubitemid 40038353)
56. Gal S et al. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J Neural Transm Suppl 2006; 70: 447-456. (Pubitemid 44622237)
57. del Monte-Millán M et al. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. J Mol Neurosci 2006; 30: 85-88.
58. Castro A, Martinez A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 2006; 12: 4377-4387. (Pubitemid 44718295)
59. Bartolini M et al. Beta-amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 2003; 65: 407-416. (Pubitemid 36084557)
60. Klein J. Phenserine. Expert Opin Investig Drugs 2007; 16: 1087-1097. (Pubitemid 47074163)
61. Eubanks LM et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 2006; 3: 773-777. (Pubitemid 46087493)
62. Bachis A et al. Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity. J Neurosci 2001; 21: 3104-3112. (Pubitemid 32323492)
63. Lusardi TA et al. The separate roles of calcium and mechanical forces in mediating cell death in mechanically injured neurons. Biorheology 2003; 40: 401-409. (Pubitemid 36164568)
64. Piazzi L et al. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett 2008; 18: 423-426.
65. Rodríguez-Franco MI et al. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem 2006; 49: 459-462. (Pubitemid 43157478)
66. Müller-Spahn F. Current use of atypical antipsychotics. Eur Psychiatry 2002; 17: 377-384. (Pubitemid 34987837)
67. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008; 68: 2269-2292.
68. Jain R. Single-action versus dual-action antidepressants. Prim Care Companion J Clin Psychiatry 2004; 6: 7-11.
69. Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009; 6: 53-77.
70. Boot J et al. Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/ norepinephrine reuptake inhibitors. Bioorg Med Chem Lett 2005; 15: 699-703. (Pubitemid 40143150)
71. Stimmel GL et al. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17: 10-21. (Pubitemid 27057115)
72. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64: 327-337. (Pubitemid 46376789)
73. Beyer CE et al. Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant. Br J Pharmacol 2009; 157: 307-319.
74. Cashman JR, Ghirmai S. Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem 2009; 17: 6890-6897.
75. Bertolini A et al. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem 2002; 9: 1033-1043. (Pubitemid 34537535)
76. Leone S et al. Dual acting anti-inflammatory drugs. Curr Top Med Chem 2007; 7: 265-275. (Pubitemid 46358660)
77. Toda N. Vasodilating b-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003; 100: 215-234. (Pubitemid 37494907)
78. Shimizu M et al. Effects of efonidipine, an L- and T-type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study. Curr Ther Res 2003; 64: 707-714. (Pubitemid 38130686)
79. Johnston CI et al. New hormonal blockade strategies in cardiovascular disease. Scand Cardiovasc J Suppl 1998; 47: 61-66. (Pubitemid 28105225)
80. Bralet J et al. Fasidotril: the first dual inhibitor of neprilysin and ACE. Cardiovasc Drug Rev 2006; 18: 1-24.
81. Laurent S et al. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension 2000; 35: 1148-1153. (Pubitemid 30327272)
82. Venugopal J. Pharmacological modulation of the natriuretic peptide system. Expert Opin Ther Pat 2003; 13: 1389.
83. Fournié-Zaluski MC et al. Dual inhibition of angiotensin- converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc Natl Acad Sci USA 1994; 91: 4072-4076. (Pubitemid 24139575)
84. Ruilope LM et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375: 1255-1266.
85. Jeng AY et al. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol Pharmacol 2002; 80: 440-449. (Pubitemid 34539420)
86. Udelson JE et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-2423. (Pubitemid 33108374)
87. He B et al. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 2010; 74: 1458-1464.
88. International Nonproprietary Names for Pharmaceutical Substances. WHO Drug Information 7 (4). 1993. Available from: http://whqlibdoc.who.int/inn/ proposed-lists/prop-INN- list70.pdf.
89. Gowda RM et al. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism. Am J Ther 2004; 11: 302-307.
90. Robinson AWet al. Use of niacin in the prevention and management of hyperlipidemia. Prog Cardiovasc Nurs 2001; 16: 14-20.
91. Chen K et al. Structure-activity relationships (SAR) research of thiourea derivatives as dual inhibitors targeting both HIV-1 capsid and human cyclophilin A. Chem Biol Drug Des 2010; 76: 25-33.
92. Lehmann M et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila somatic mutation and recombination test. Environ Mol Mutagen 2004; 43: 250-257. (Pubitemid 38702631)
93. Vigushi DM et al. Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. Med Oncol 2004; 21: 20-21.
94. López-Lázaro M et al. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat Res 2010; 696: 41-47.
95. Ganapathi SB et al. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am J Physiol Cell Physiol 2009; 296: 701-710.